Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of the Use of Sodium Pyruvate Bronchodilation in Asthmatics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. A physician diagnosis of asthma~2. Age years old~3. Symptoms consistent with asthma for at least 6 months~4. Current asthma medications: Short-acting inhaled beta agonists as needed for control of asthma symptoms with or without a low to medium dose of an ICS, as defined in the table below and if on a ICS may also be on a long-acting beta agonist provided it is withheld for 24 hours prior to the testing days.~   Inhaled Corticosteroid Dose less than or equal to:~   Beclomethasone-HFA 480 µg/day Budesonide-DPI 1000 µg/day Flunisolide 2000 µg/day Fluticasone 500 µg/day Triamcinolone 2000 µg/day~5. FEV1 at screening 50-80% predicted (Hankinson6)~6. Reversibility with albuterol of 12% and 200 ml FEV1FEV1 at 30 minutes.~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).